Onco Actu du 5 juillet 2017

	1. Biologie
Scientists Are Not So Hot At Predicting Which Cancer Studies Will Succeed [NPR] "Most researchers overestimated the ability of repetition studies to have effects that were as significant as the original study," Kimmelman says. And that over-optimism ran pretty much across the board. "There wasn't really a big difference between trainees and experts," he says.
	3.1.1 Tabac - e-cigs
E-cigarettes are some young people’s training wheels for smoking. Here’s the evidence [The Conversation] A series of nine recent studies has shown young people who try e-cigarettes are more likely to go on to smoke cigarettes by the next time they are interviewed. These studies all considered young people who had not smoked a cigarette, and then compared smoking between those who did, and did not use e-cigarettes at the start.
	4.12 Biopsies liquides
ANGLE Reports Successful Headline Data in US and European Ovarian Cancer Studies in 400 Patients [ANGLE] The successful results announced today enable ANGLE to move into the next phase of development of a commercial blood test addressing an estimated market size of £300 million per annum.
Blood test by Britain's Angle detects ovarian cancer in study [Reuters] The performance of the test would now be validated in another study designed to meet European CE Mark and US FDA regulatory requirements.
	4.2 Dép., diag. & prono. - Génome
Driving the genomic dream for the NHS [PHG Foundation] Whilst some of her proposals may provoke considerable debate (of which more later), they nevertheless manage to combine inspiring vision with robust pragmatism – which is not easy to achieve. Bravo, CMO!
Greater access to genetic testing needed for cancer diagnosis and treatment [Cancer Research UK] The report recommends that within 5 years training should be available to current and future clinicians and that all patients should be being offered genomic tests just as readily as they’re given MRI scans today.
	5. Traitements
Judging the benefits and harms of medicines [BMJ] Only trustworthy evidence will earn the public’s trust.
	5.3 Traitements - FDA, EMA, NICE...
Is FDA Too Slow? Researchers Debunk Claims [RAPS] "This crude depiction ignores industry's contribution to the clock after clinical trials are completed but before the FDA receives the formal application," they write. Instead, the authors argue that there's little room on FDA's end to speed the review of new drugs.
EMA and EUnetHTA step up interaction to align data requirements [EMA] A new joint platform for parallel consultation will provide advice to medicine developers and facilitate access to medicines for patients.
	5.6 ESMO
Metastatic Colorectal Cancer: Beyond RAS and BRAF [ESMO] Dr Filippo Pietrantonio of the Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy said in an oral presentation at the ESMO World Congress on Gastrointestinal Cancer 2017 that RET rearrangements define a new and rare molecular subtype of metastatic colorectal cancer (mCRC) associated with unfavourable prognosis and specific clinicopathological and molecular features.
	6. Lutte contre les cancers
The little-known cancer that 30,000 people are living with [The Telegraph] Collectively, neuroendocrine cancers (NETs) are more common than testicular, ovarian, cervical and thyroid cancers, but are much less well-known and more likely to be misdiagnosed.
Chinese Hospital Invites Cancer Experts to Help Treat Nobel Laureate [NY Times] Wednesday’s statement, which was posted on the Shenyang Justice Ministry’s website, did not mention which foreign doctors had been invited or whether any had responded.
	6.1 Observation
New maps reveal cancer levels across Australia, and across the social strata [The Conversation] Our analysis of cancer incidence rates showed a mixed picture when it comes to the link between how well-off you are and how likely you are to receive a cancer diagnosis.
	6.10 Politiques
Europe’s next big science-funding programme urged to double its budget [Nature] Influential report suggests simpler, more citizen-friendly system for post-2020 EU research funding.
	6.7.2 Applis
Google spin-off deploys wearable electronics for huge health study [Nature] One challenge in all these efforts is keeping people engaged over many months. Verily is considering using games to sustain participation. But Hood doubts the long-term efficacy of that approach. He says Arivale’s clients stick with their programme because of the monthly visits to a coach. “It’s a lot like therapy,” he says, “they become your mother or father.”